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ABSTRACT
Schnitzler syndrome is a rare inflammatory disorder characterized by chronic urticarial 
rash, monoclonal gammopathy, periodic fever, arthralgia/arthritis and bone pain. 
However, the results of management of Schnitzler syndrome are often disappointing and 
its treatment remains a challenge. No cases of spontaneous complete remission have 
been reported. Anakinra is an interleukin 1 receptor antagonist used for the treatment 
of rheumatoid arthritis, and has been reported to be universally effective for Schnitzler 
syndrome. Here, we report the first Asian patient with Schnitzler syndrome who 
achieved long-term control with anakinra, after previous failures with various therapeutic 
approaches.
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Schnitzler syndrome was first described in 1972 by the 
French dermatologist, Schnitzler.1 It is a rare disabling dis-
order diagnosed on the basis of a chronic urticarial rash and 
a monoclonal immunoglobulin M (IgM) gammopathy, ac-
companied by at least two of the following features: inter-
mittent unexplained fever, arthralgia or arthritis, bone pain, 
lymphadenopathy, hepatosplenomegaly, elevated erythro-
cyte sedimentation rate or leukocytosis, and abnormal find-
ings on bone morphologic investigations.2 Treatment is 
often difficult and no universally effective treatment is cur-
rently available. Here we report the first Asian patient with 
Schnitzler syndrome who achieved satisfactory long-term 
control with anakinra.
Case report
A 64-year-old male with a past history of arrhythmia was 
referred to our outpatient clinic in 2007. He presented with 
a 3-year history of an intermittent, widespread, non-pruritic 
urticarial rash. The urticarial rash lasted from several hours 
to more than a day. He had been diagnosed with chronic 
urticaria by several dermatologists since 2004. The symp-
toms were resistant to different antihistamines but could be 
partially controlled with oral corticosteroids. Two years after 
the onset of these symptoms, intermittent fever (peaks over 
39°C) with chills, malaise, muscle soreness and polyarthral-
gia were detected. He presented at our dermatology clinic 
in November 2007. Physical examination revealed numer-
ous variously sized, irregularly-shaped wheals on the trunk, 
and upper and lower extremities (Figures 1A and 1B). The 
rash was not triggered by any precipitating factors. Neither 
hepatosplenomegaly nor palpable lymph nodes were noted. 
Laboratory tests revealed an increased erythrocyte sedimen-
tation rate (ESR) (> 110 mm/h , normal < 20), anemia (hemo-
globin 112 g/L), leukocytosis (white cell count 14.27 ˜  103/μL 
with 10.8 ˜  103/μL neutrophils), and platelet count 335 ˜  
103/μL. Biochemical investigation revealed increased ferritin 
(1025 pmol/L, normal 59.8–847 pmol/L) with decreased iron 
(10.4 μmol/L, normal 13.4–31.9 μmol/L) and total iron-binding 
capacity (37.6 μmol/L, normal 49.2–59.4 μmol/L). Complement 
levels (C3 1.61 g/L, normal 0.816–1.814 g/L; C4 0.131 g/L, 
normal 0.275 ± 0.107 g/L) and fibrinogen (9.86 μmol/L, 
normal 4.81–10.64 μmol/L) were normal. Tumor necrosis 
factor (TNF)-α (8.93 pg/mL, normal < 8.1 pg/mL) and β-2 
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microglobulin levels (2.3 mg/L, normal 0.7–1.8 mg/L) were 
slightly increased. Serum protein electrophoresis showed 
increased alpha-1 and alpha-2 globulins, and a small parapro-
tein peak in the gamma region. The IgM level was 1 250 mg/L 
(normal range, 1605.7 ± 722 mg/L), the IgG level was 21.80 g/L 
(normal range, 14.20 ± 27.98 g/L) and the IgA level was 
4 700 mg/L (normal range, 2593.4 ± 828.4 mg/L). Serum im-
munofixation electrophoresis study revealed a thin band of 
IgM/kappa monoclonal gammopathy. A small amount of 
kappa chain Bence-Jones protein was found in urine by im-
munofixation electrophoresis. Antinuclear antibodies, rheu-
matoid factor and cryoglobulins were all negative. Hepatitis 
B and C were excluded by serologic examinations. Biopsy 
of affected skin demonstrated perivascular and interstitial 
neutrophilic infiltration in the upper dermis. Bone marrow 
biopsy showed erythroid hyperplasia without malignant cells. 
A computed tomographic scan of the chest, abdomen and 
pelvis was negative for proliferative disorders. Bone scintig-
raphy showed increased uptake in the lower cervical, upper 
thoracic and lower lumbar spines, the right acromion, and 
the right anterior sixth rib.
Based on the symptoms and results, which included chronic 
urticaria, monoclonal gammopathy, fever, arthralgia, bone 
pain and elevated erythrocyte sedimentation rate, a diag-
nosis of Schnitzler syndrome was made. The patient was 
initially treated with prednisolone (10 mg/day), colchicine 
(1 mg/day), potassium iodine (900 mg/day), hydroxychloro-
quine (800 mg/day), indomethacin (75 mg/day), fexofenadine 
(120 mg/day), levocetirizine (5 mg/day), doxepin (50 mg/day), 
and buclizine (25 mg/day), either alone or in combination, 
but no significant improvement was noted (Figure 2). A trial 
of thalidomide (100 mg/day) had to be stopped because of 
severe drowsiness. Six months after the diagnosis of Schnitzler 
syndrome, the patient was commenced on subcutaneous 
anakinra (100 mg/day) with diclofenac (100 mg/day). The 
urticarial lesions and fever had completely disappeared 
within 10 hours of the first injection, and the bone pain, 
arthralgia and malaise had disappeared within 1–2 days. 
Hemoglobin, white cell count, serum iron and ferritin, serum 
IgG and IgA levels normalized; the ESR was reduced and 
returned to normal (ESR 1h, 17 mm/h). The IgM monoclonal 
gammopathy persisted, but paraprotein fell from 972 mg/dL 
to 429 mg/dL. No Bence-Jones protein was found in the 
urine (Table 1). The patient remained symptom-free at 11 




Figure 1 (A,B) Many non-pruritic, irregularly shaped, erythematous, edematous wheals, mainly on the trunk and extremities. (C,D) Histologic ex-
aminations revealed perivascular and interstitial neutrophilic and lymphocytic infiltration in the superficial dermis (H&E, 200˜ , 400˜ , respectively).
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Discussion
Schnitzler syndrome is a rare inflammatory disorder of un-
known pathophysiology, presenting as chronic refractory 
urticaria and arthralgia/arthritis. The main clinicopathologic 
differential diagnosis consists of a group of diseases charac-
terized by neutrophilic urticarial dermatosis with systemic 
diseases, namely adult-onset Still’s disease, lupus erythema-
tosus and hereditary autoinflammatory fever syndrome. 
Schnitzler syndrome is also characterized by monoclonal 
gammopathy, periodic fever and bone pain, but its precise 
pathogenesis remains unclear. Some studies3,4 have reported 
IgM deposits around the superficial dermal vessels, within the 
superficial dermis and along the dermal-epidermal junction. 
Lipsker et al4 revealed the presence of anti-skin IgM au-
toantibody, with the same isotype as circulating monoclonal 
immunoglobulins, in some patients, and suggested that in 
situ IgM-mediated complement activation and subsequent 
tissue damage was responsible for the skin manifestations 
of Schnitzler syndrome. However, these IgM depositions 
could only be detected in 25% of patients with Schnitzler 
syndrome. In another study,5 a patient with Schnitzler syn-
drome received the anti-CD20 antibody rituximab for 5 weeks, 
resulting in decreased peripheral B-cell counts and IgM 
levels, though the urticarial lesions, fatigue and bone pain 
persisted. Polyclonal increases in IgA and IgG levels had 
been documented in two case reports.6,7 Moreover, IgA 
monoclonal gammopathy has been reported in Schnitzler 
syndrome.8 It has been suggested that anti-interleukin (IL)1α 
IgA auto antibodies are more frequent in Schnitzler’s syndrome 
than in controls.7 However, the role of these monoclonal or 
polyclonal paraproteins have not been fully established. It 
is still unclear if the monoclonal paraprotein or elevated 
immunoglobulin is causative in nature, or simply a result of 
continuous antigenic stimulation. Further studies are needed 
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Figure 2 Treatment course of the patient.
Table 1 Results of laboratory investigations.
Laboratory 
Pre-anakinra Post-anakinrainvestigations
ESR (mm/h, 1 hr) > 110 17
WBC (˜109/L) 14.27 6.48
Hemoglobin (g/L) 112 130
Ferritin (pmol/L) 1025 308
Iron (μmol/L) 10.4 17.7
TIBC (μmol/L) 37.6 44.8
Urine IFE Bence-Jones  Bence-Jones
 protein (+) protein (–)
IgG (g/L) 21.8 14.1
IgM (mg/L) 1250 2510
IgA (mg/L) 4700 2260
Serum IFE IgM/kappa  IgM/kappa 
 monoclonal monoclonal
 gammopathy (+) gammopathy (+)
TNF-α (pg/mL) 8.93 NA
C3/C4 (g/L) 1.61/0.13 NA
β-2 microglobulin (mg/L) 2.3 NA
ESR = erythrocyte sedimentation rate; WBC = white blood count; TIBC = 
total iron-binding capacity; IFE = immunofixation electrophoresis; Ig = 
immunoglobulin; TNF = tumor necrosis factor; NA = not available; C3/
C4 = complement component C3/C4.
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The role of cytokines in Schnitzler syndrome has not 
been fully established. In a study by de Kleijn et al,9 only 
slight elevations of IL-6 were observed in one patient with 
Schnitzler syndrome, and no increases in circulating levels 
of IL-1β or TNFα were found. Normal plasma IL-1 levels 
have also been observed in other cases.10,11 One study,12 
however, has proposed that uncontrolled activation of 
IL-1α plays an important role in the pathophysiology of 
Schnitzler syndrome. Saurat et al12 found remarkably in-
creased IgG-type autoantibody directed against IL-1α in the 
serum of six out of nine patients with Schnitzler syndrome. 
They postulated that anti-IL-1α IgG could prolong the half 
life of IL-1α, change its tissue distribution, and enhance its 
effects,12 which might account for some of the symptoms 
and signs of Schnitzler syndrome. However, it has not been 
found in all patients with Schnitzler syndrome, and was 
detected in 18% of healthy individuals.13
Treatment of Schnitzler syndrome remains a challenge, 
although many therapeutic approaches, including gluco-
corticosteroids, non-steroidal anti-inflammatory drugs, 
colchicine, dapsone, thalidomide, interferon-α, rituximab, 
immunoglobulins, methotrexate, cyclophosphamide, purine 
analogs, plasma exchange and photochemotherapy have 
all been described in the literature. The symptoms and signs 
in these patients were usually partially responsive to oral 
corticosteroids, but long-term, high-dose therapy was required 
to achieve effective control. Schartz et al14 successfully 
treated a Schnitzler syndrome patient with interferon-α and 
suggested that it might induce high circulating levels of IL-1 
receptor antagonists in humans.
Anakinra, a recombinant form of IL-1 receptor antagonist, 
competitively inhibits the binding of IL-1α and IL-1β to the IL-1 
receptor. Rheumatologists and pediatricians have successfully 
used it to treat rheumatoid arthritis and autoinflammatory dis-
eases such as Muckle-Wells syndrome, TNF-associated pe-
riodic syndrome, and hyper-IgD syndrome.5 Because of the 
clinical similarities between Schnitzler syndrome and some 
autoinflammatory diseases with increased IL-1 production that 
were effectively treated with anakinra, anakinra has been used 
for the management of Schnitzler syndrome in many studies. 
Ryan et al15 examined the ex vivo production of cytokines and 
the effects of inhibition of IL-1 in Schnitzler syndrome. The 
IL-1 inhibitor, IL-trap, and the caspase-inhibitor, YVAD, sig-
nificantly reduced the hypersecretion of IL-1, IL-6 and TNF, 
which was correlated with clinical remission.
To date, 17 cases with excellent responses to anakinra 
have been reported.3,5–7,10,15–23 All the reported cases, how-
ever, have been Caucasians, and no Asian cases have been 
reported. Most of the patients had failed various other treat-
ment regimens before initiation of anakinra therapy. Remis-
sion of fever, and skin rash was always induced within 24 
hours of anakinra treatment at 100 mg/day. In some of these 
patients, bone pain and arthralgia took days to weeks to 
resolve. The symptoms recurred within 24–48 hours when 
anakinra was discontinued, but usually disappeared again 
after resumption of treatment,3,10,17,18 as noted in our pa-
tient. Signs of systemic inflammation, such as elevated ESR, 
C-reactive protein, ferritin and leukocytosis were observed 
in patients with Schnitzler syndrome; these remained in-
creased throughout the course of the disease, peaking dur-
ing exacerbation. These serologic parameters were usually 
reduced and normalized after anakinra treatment. The longest 
follow-up period in a patient continuously treated with 
anakinra was 21 months.17 The only recorded adverse ef-
fect of anakinra is painful erythematous eruption at the injec-
tion site, which occurred in three out of these 17 patients.3,6,18 
Despite the therapeutic effects of anakinra, long-term follow-
up is warranted because 15% of patients with Schnitzler 
syndrome go on to develop lymphoproliferative disorders 
within 10–20 years.24
Schnitzler syndrome is a rare cause of chronic urticaria 
and may be complicated by subsequent lymphoprolifera-
tive disorders and systemic amyloidosis.8 In cases of chronic 
refractory urticaria, serum protein electrophoresis can be 
performed to rule out the possibility of Schnitzler syndrome. 
The prompt and dramatic response in our patient, as well 
as in other reports, suggests that anakinra might be a prom-
ising and effective option for the treatment of Schnitzler 
syndrome. It also underlines the pivotal role of IL-1 in the 
pathogenesis of Schnitzler syndrome. However, further long-
term studies are warranted to determine if anakinra can re-
duce the incidences of lymphoproliferative diseases and 
amyloidosis in patients with Schnitzler syndrome.
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